Research programme: complement inhibitors - Amyndas Pharmaceuticals

Drug Profile

Research programme: complement inhibitors - Amyndas Pharmaceuticals

Alternative Names: AMANDEN; AMY 101; AMY 201; Compsorbin; Compstatin analogues - Amyndas; Cp 40

Latest Information Update: 07 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Pennsylvania
  • Developer Amyndas Pharmaceuticals
  • Class Peptides
  • Mechanism of Action Complement C3 inhibitors; Complement C3-C5 convertases inhibitors; Complement factor H inhibitors; Protein-protein interaction inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria; Membranous glomerulonephritis
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Membranous glomerulonephritis; Paroxysmal nocturnal haemoglobinuria; Periodontitis; Renal failure; Renal transplant rejection

Most Recent Events

  • 27 Feb 2017 Amyndas has issued and pending patents with USPTO and PCT for complement inhibitors (Amyndas website, February 2017)
  • 27 Feb 2017 Preclinical trials in Renal failure in USA (SC) (Amyndas website, February 2017)
  • 27 Feb 2017 Preclinical trials in Renal transplant rejection (Prevention) in USA (SC) (Amyndas website, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top